Discontinuation of neoadjuvant therapy does not influence postoperative short-term outcomes in elderly patients (≥ 70 years) with resectable gastric cancer: a population-based study from the dutch upper gastrointestinal cancer audit (DUCA) data

Jingpu Wang,Zhouqiao Wu,Eline M. de Groot,Alexandre Challine,Nadia Haj Mohammad,Stella Mook,Lucas Goense,Jelle P. Ruurda,Richard van Hillegersberg
DOI: https://doi.org/10.1007/s10120-024-01522-5
2024-08-22
Gastric Cancer
Abstract:For the elderly patients with gastric cancer, it may be more challenging to tolerate complete neoadjuvant therapy (NAT). The impact of discontinued NAT on the surgical safety and pathological outcomes of elderly patients with poor tolerance remains poorly understood.
oncology,gastroenterology & hepatology
What problem does this paper attempt to address?